SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

SARS-CoV-2 between 2021 and 2023 developed long-COVID, and in more than half of them the symptoms persisted for two years.

The SARS-CoV-2 virus elicits humoral immune responses with the production of IgG, IgM and IgA isotypes. Different isotypes may predominate at different times post-infection. IgM and IgA isotypes ...

Today in BMC Medicine, researchers in Catalonia, Spain, estimate that 23% of adult COVID-19 survivors develop long COVID, ...

SARS-CoV-2 is a case in point ... and therefore surrogate markers of this activity (i.e., perhaps quantitative anti-RBD IgG levels) will be key management tools. The emergence of the B.1.1.7 ...

When the COVID-19 pandemic first began, we saw how quickly the SARS-CoV-2 virus evolved. New variants emerged with mutations ...

According to a study of the COVICAT cohort, almost one in four people infected with SARS-CoV-2 suffered from long-COVID. Long ...

A team has found two antibodies that can work together to neutralize the virus that causes COVID-19 in all its current known variations in a laboratory environment. More research is needed, but the ...

SARS-CoV-2 between 2021 and 2023 developed long-COVID, and in more than half of them the symptoms persisted for two years ...

A Stanford-led team has found two antibodies that can work together to defeat all SARS-CoV-2 variants. More research is needed, but the approach could help in the development of treatments to keep ...

To verify the ELISpot data, they cultivated ASCs in vitro and assessed IgG specific for Flu, Tet, and SARS-CoV-2 spike ...

SARS-CoV-2 between 2021 and 2023 developed long-COVID, and in more than half of them the symptoms persisted for two years.